Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Rezatapopt · PC-14586

Small molecule · Modulator of p53 Y220C mutant protein (TP53) · developed by PMV Pharmaceuticals

Phase 1/2 Most advanced trial
PMVP Developer
3 Registered trials

What is Rezatapopt?

Rezatapopt is an orally bioavailable small molecule that binds the crevice created by the TP53 Y220C mutation. It is designed to restore wild-type p53 protein structure and activity, which blocks tumor cell cycle progression and induces apoptosis in tumor cells carrying the mutant. It is studied in advanced solid tumors, including lung, ovarian, endometrial, breast, colorectal and head and neck cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PC-14586, [14C]-PC14586
Drug type
Small molecule
Targets
p53 Y220C mutant protein (TP53)
Mechanism
Modulator of p53 Y220C mutant protein (TP53)
Pathways
p53 pathway, cell cycle progression, apoptosis
Therapy area
Oncology
Developer
PMV Pharmaceuticals, Inc (PMVP)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
5W59S33KC9

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04585750 Phase 1/2 Advanced Solid Tumor Recruiting PMVP
NCT06054464 Phase 1 Healthy Volunteers Completed PMVP
NCT05523687 Phase 1 Healthy Male Volunteers Completed PMVP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Malignant NeoplasmAdvanced Solid TumorBreast CancerColorectal CancerEndometrial CancerGall Bladder CancerHead and Neck CancerLocally AdvancedLung CancerMetastatic CancerMetastatic Solid TumorOther CancerOvarian CancerProstate Cancer

Other drugs acting on TP53

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PMVP page.

Follow PMVP, the company behind Rezatapopt

See PMVP's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PMVP catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.